B. Riley reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report issued on Monday, Marketbeat.com reports. The brokerage currently has a $205.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $220.00. B. Riley also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.60) EPS, FY2017 earnings at ($5.32) EPS, Q2 2018 earnings at ($1.46) EPS, Q3 2018 earnings at ($1.14) EPS, Q4 2018 earnings at ($1.20) EPS and FY2018 earnings at ($4.90) EPS.
Several other brokerages have also issued reports on ALNY. Goldman Sachs Group raised Alnylam Pharmaceuticals from a neutral rating to a buy rating and upped their price target for the company from $62.00 to $163.00 in a research note on Monday, October 2nd. Jefferies Group reaffirmed a buy rating and set a $102.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, September 18th. Needham & Company LLC upped their price target on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the company a buy rating in a research note on Wednesday, September 20th. Cowen reaffirmed an outperform rating and set a $117.00 price target (up previously from $93.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $14.71 price target (down previously from $188.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 2nd. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Alnylam Pharmaceuticals presently has an average rating of Buy and an average target price of $121.20.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $128.05 on Monday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63. The stock has a market capitalization of $12,590.00, a price-to-earnings ratio of -24.39 and a beta of 2.98.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same period last year, the company earned ($1.21) EPS. The company’s revenue was up 24.8% compared to the same quarter last year. analysts forecast that Alnylam Pharmaceuticals will post -5.21 EPS for the current fiscal year.
In other news, SVP Laurie Keating sold 30,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the sale, the senior vice president now owns 41,500 shares of the company’s stock, valued at $5,639,435. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO John Maraganore sold 74,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total value of $9,387,640.00. Following the sale, the chief executive officer now directly owns 223,710 shares in the company, valued at approximately $28,379,850.60. The disclosure for this sale can be found here. Insiders sold 274,075 shares of company stock worth $35,356,089 in the last three months. Insiders own 4.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALNY. FMR LLC raised its position in shares of Alnylam Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after purchasing an additional 815,270 shares during the period. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 13.4% during the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock worth $512,020,000 after purchasing an additional 759,295 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $53,226,000. Orbimed Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 69.7% during the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after purchasing an additional 445,600 shares during the period. Finally, BlackRock Inc. raised its position in shares of Alnylam Pharmaceuticals by 9.3% during the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock worth $413,811,000 after purchasing an additional 441,957 shares during the period. 88.39% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/12/alnylam-pharmaceuticals-alny-earns-buy-rating-from-b-riley.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.